CompletedPhase 2NCT00015964
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Principal Investigator
- Everett Vokes, MDUniversity of Chicago
- Intervention
- ZD1839(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2001 – 2005
Study locations (11)
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
- Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, United States
- Evanston Northwestern Health Care, Evanston, Illinois, United States
- Ingalls Memorial Hospital, Harvey, Illinois, United States
- Columbia LaGrange Memorial Hospital, LaGrange, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C., South Bend, Indiana, United States
- Oncology Care Associates, P.L.L.C., Saint Joseph, Michigan, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00015964 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →